Synergistic treatment of cancer using immunomers in...

Details Synergistic treatment of cancer using immunomers in... Synergistic treatment of cancer using immunomers in...

2011-01-25

2011-01-25

Huff, Sheela J (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07875594

ABSTRACT:
The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

REFERENCES:
patent: 5366878 (1994-11-01), Pedersen et al.
patent: 5635377 (1997-06-01), Pedersen et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5912332 (1999-06-01), Agrawal et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6426334 (2002-07-01), Agrawal et al.
patent: 7276489 (2007-10-01), Agrawal et al.
patent: 7405285 (2008-07-01), Agrawal et al.
patent: 7427405 (2008-09-01), Agrawal et al.
patent: 7498425 (2009-03-01), Agrawal et al.
patent: 7498426 (2009-03-01), Agrawal et al.
patent: 7517862 (2009-04-01), Agrawal et al.
patent: 7566702 (2009-07-01), Agrawal et al.
patent: 7595305 (2009-09-01), Agrawal et al.
patent: 7709617 (2010-05-01), Kandimalla et al.
patent: 2001/0034330 (2001-10-01), Kensil
patent: 2002/0132995 (2002-09-01), Agrawal et al.
patent: 2002/0156033 (2002-10-01), Bratzler et al.
patent: 2003/0199466 (2003-10-01), Fearon et al.
patent: 2005/0059619 (2005-03-01), Krieg et al.
patent: WO 98/49288 (1998-11-01), None
patent: WO 01/12804 (2001-02-01), None
patent: PCT/US01/13682 (2001-04-01), None
patent: PCT/US01/30137 (2001-07-01), None
patent: WO 01/55370 (2001-08-01), None
patent: 01/97843 (2001-12-01), None
patent: 02/26757 (2002-04-01), None
patent: WO 03/035836 (2003-05-01), None
Kandimalla et al (Bioconjugate Chem., vol. 13 p. 966 2002.
Donnelly et al (Nature Medicine, 2003, 9/11:1354-1356).
Bitton R. J. (Current Opinion in Molecular Therapeutics, 2004, 6/1:17-25).
Yu et al BBRC vol. 297 p. 83 (Sep. 4, 2002).
Berenbaum (“Synergy, additivism and antagonism in immunosuppression,” Clin exp Immunol 28:1-18, 1977).
Tallarida (Drug Synergism and Dose-effect Analysis, Chapman & Hall/CRC, Boca Raton, 2000, pp. 1-13).
Wiesenthal (http://weisenthal.org/feedback. html, Feb. 4, 2002.
Agrawal et al (Trends in Molecular Medicine, 2002, 8/3:114-120).
(DeGruijl et al, Nature Medicine, 1999, 5/10:1124-1125, see p. 1124, col. 1).
Weiner (J. Leukocyte Biology vol. 68 p. 455 (2000).
Ballas et al (J. Immunol. vol. 167 p. 4878 (2001).
Kandimalla et al, PNAS,vol. 100 p. 14303 (2003).
Kuramoto et al. “Oligonucleotide Sequences Required for Natural Killer Cell Activation” (1992) Jpn. J. Cancer Res. 83:1128-1131.
Krieg et al. “CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation”, (1995) Nature 374: 546-549.
Liang et al. “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides”, (1996) J. Clin. Invest. 98: 1119-1129.
Zhao et al. “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation”, (1996) Biochem. Pharmacol. 51:173-182.
Zhao et al. “Modulation of Oligonucleotide-Induced Immune Stimulation by Cyclodextrin Analogs”, (1996) Biochem. Pharmacol. 52:1537-1544.
Zhao et al. “Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotide in Mice”, (1997) Antisense Nucleic Acid Drug Dev. 495-502.
McCluskie et al. “Cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice”, (1998) J. Immunol. 161:4463-4466.
Moldoveanu et al. “CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal Immunication with Influenza Virus”, (1998) Vaccine 16:1216-1224.
Zhao et al. “Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity”, (1999) Bioorg. Med. Chem. Lett. 9:3453-3458.
Zhao et al. “Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside”, (2000) Bioorg. Med. Chem. Lett. 19:1051-1054.
Yu et al. “Accessible 5′-End of CpG-Containing Phosphorothioate Oligodeoxynucleotides is Essential for Immunostimulatory Activity”, (2000) Bioorg. Med. Chem. Lett. 10:2585-2588.
Kandimalla et al. “Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships” (2001) Bioorg. Med. Chem. 9:807-813.
Yu et al. “Modulation of Immunostimulatory Activity of CpG Oligonucleotides by Site-Specific Deletion of Nucleobases”, (2001) Bioorg. Med. Chem. Lett. 11:2263-2267.
Warren et al., “Synergism Between Cytosine-Guanine Oligodeoxynucleotides and Monoclonal Antibody in the Treatment of Lymphoma”, Seminars in. Oncol. 2002, vol. 29(1) (2). pp. 93-97.
Cheng et al., “Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine”, J. Nat. Cancer Inst. 2003, vol. 95(5), pp. 399-409.
Weigel et al., “CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Mutine Model of Rhabdomyosarcoma”, Clin. Cancer Resear. 2003, vol. 9, pp. 3105-3114.
Kandimalla et al., “A Dinucleotide Motif in Oligonucleotides Shows Potent Immunomodulatory Activity and Overrides Species-Specific Recognition Observed with CpG Motif”, PNAS 2003, vol. 100(24), pp. 14303-14308.

Affiliated with

Also associated with

Rating

Synergistic treatment of cancer using immunomers in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synergistic treatment of cancer using immunomers in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic treatment of cancer using immunomers in... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2731198